Bharat Biotech hits back at Critics, says 200 percent honest trials were conducted

Published On 2021-01-05 06:00 GMT | Update On 2021-01-05 10:18 GMT

Hyderabad: Bharat Biotech Chairman Krishna Ella said on Monday that the company does not deserve the backlash it is receiving in the light of the India's drugs regulator granting its coronavirus vaccine Covaxin approval for emergency use.

"Don't accuse us of inexperience. We are a global company... have manufactured 16 vaccines," he said, highlighting that "200 per cent honest" clinical trials were conducted.

Ella said the company conducts clinical trials not only in India but also many other countries.

His comments assume significance as Covaxin has been given an emergency approval despite allegedly only two of the required three trial phases being completed.

However, Ella pointed at the number of journal articles Bharat Biotech published and claimed that it was the first to identify Zika virus and file a patent for Zika and Chikungunya viruses.

Bharat Biotech was the only company to have a Bio Safety Level 3 (BSL- 3) production facility, he noted.

"We do 200 per cent honest clinical trials and yet we receive a backlash. If I am wrong, tell me. Some companies have branded me 'water'. I want to deny that. We are scientists," he said.

Article Source : IANS

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

MD Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Bharat Biotech hits back at Critics, says 200 percent honest trials were conducted

Similar News

Health Ministry Drafts Rule to Debar Pharma Applicants Submitting Fake or Misleading Documents

CDSCO Panel Seeks Anesthesiology Expert Review for AIIMS Raipur Trial on Gabapentin, Melatonin, Clonidine FDC

Birds, Lizards, and Broken Protocols: USFDA Slams Hetero Labs Over Filthy Warehouse, Missing Records

Boehringer Ingelheim acquires license from Kyowa Kirin to develop autoimmune diseases treatment

Sanofi India net profit falls 7.9 percent in Q2

Merck, Eisai to shut down late stage trial of liver cancer therapy

GSK pulmonary neuroendocrine carcinoma treatment gets Orphan Drug Designation in EU

Natco Pharma unveils Everolimus tablets 1mg in US